Use your antibodies-online credentials, if available.
Il n’y a pas de produits dans votre liste de comparaison.
Votre panier est vide.
Afficher toutes les espèces
Afficher tous les synonymes
Sélectionnez vos espèces et l'application
anti-Human SPRY1 Anticorps:
anti-Rat (Rattus) SPRY1 Anticorps:
anti-Mouse (Murine) SPRY1 Anticorps:
Vous arrivez à notre recherche pré-filtrée.
Human Monoclonal SPRY1 Primary Antibody pour IHC (p), ELISA - ABIN564437
Moghaddam, Amini, Wei, Pourgholami, Morris: Initial report on differential expression of sprouty proteins 1 and 2 in human epithelial ovarian cancer cell lines. dans Journal of oncology 2012
Show all 2 Pubmed References
Human Polyclonal SPRY1 Primary Antibody pour ELISA, WB - ABIN564436
Mekkawy, De Bock, Lin, Morris, Wang, Pourgholami: Novel protein interactors of urokinase-type plasminogen activator receptor. dans Biochemical and biophysical research communications 2010
Human Polyclonal SPRY1 Primary Antibody pour ELISA, IHC - ABIN4355747
Hanafusa, Torii, Yasunaga, Matsumoto, Nishida: Shp2, an SH2-containing protein-tyrosine phosphatase, positively regulates receptor tyrosine kinase signaling by dephosphorylating and inactivating the inhibitor Sprouty. dans The Journal of biological chemistry 2004
Although the expression of SPRY1 was low when compared with other tumors, SPRY1 was variably expressed in primary Ewing sarcoma tumors and higher expression levels were significantly associated with improved outcome in a large patient cohort.
SPRY1 and SPRY2 (Montrer SPRY2 Anticorps) mRNA transcripts were significantly upregulated in human CRC (Montrer CALR Anticorps). Suppression of SPRY2 (Montrer SPRY2 Anticorps) repressed AKT2 (Montrer AKT2 Anticorps) and EMT (Montrer ITK Anticorps)-inducing transcription factors and significantly increased E-cadherin (Montrer CDH1 Anticorps) expression. Concurrent downregulation of SPRY1 and SPRY2 (Montrer SPRY2 Anticorps) also increased E-cadherin (Montrer CDH1 Anticorps) and suppressed mesenchymal markers in colon cancer cells.
Spry1 plays a selective role in at least a subset of triple-negative breast cancer to promote the malignant phenotype via enhancing EGF (Montrer EGF Anticorps)-mediated mesenchymal phenotype.
Suppression of SPRY1 by age-associated methylation inhibits the replenishment of the muscle stem cell pool.
Cosuppression of Sprouty and Sprouty-related negative regulators of FGF signalling in prostate cancer
There is an inverse correlation between the expression of Spry1 and growth, proliferation, invasion and migration of ovarian cancer cells.
A random population of LNCaP prostate cancer cells comprises a heterogeneous group of cells with different androgen-deprivation sensitivities and potential for invasiveness; expression levels of 2 genes known to be regulated by miR (Montrer MLXIP Anticorps)-21, an androgen-regulated microRNA, SPRY1 and JAG1 (Montrer JAG1 Anticorps) were lower in an androgen insensitive clone, than an androgen sensitive clone.
The Spry1 acts as a sensor of mitogenic activity that not only attenuates RTK signaling but also induces a cellular senescence response to avoid uncontrolled proliferation.
Spry1 and Spry4 (Montrer SPRY4 Anticorps) have opposing roles in VSMC phenotypic modulation, and Spry1 maintains the VSMC differentiation phenotype in vitro in part through an Akt (Montrer AKT1 Anticorps)/FoxO (Montrer FOXO3 Anticorps)/myocardin (Montrer MYOCD Anticorps) pathway.
Re-expression of SPRY1, a repressed target of BCL11B (Montrer BCL11B Anticorps), limits the transformation capacity of Ewing sarcoma cells.
The results show that lnc-Spry1 could act as an early mediator of TGF-beta (Montrer TGFB1 Anticorps) signaling and reveal different roles for a long noncoding RNA in modulating transcriptional and posttranscriptional gene expression.
modulation of stromal paracrine signaling and extracellular matrix remodeling by SPRY1 regulates mammary epithelial morphogenesis during postnatal development.
Here, we present a novel mouse model of pheochromocytoma consisting of double-heterozygous mice for Pten and Sprouty1 (Spry1), which leads to pheochromocytomas that appear at earlier onset and grow at a higher rate than those from Pten+/- mice.
Sprouty gain of function disrupts lens cellular processes and growth by restricting receptor tyrosine kinase (Montrer ERBB3 Anticorps) signaling.
In vivo analysis of thyroid glands from Spry1 knockout mice reveals that Spry1 induces a senescence-associated secretory phenotype via activation of the NFkappaB pathway.
showed that hSpry1 overexpression prevents VEGF secretion
Spry1 and Spry2 (Montrer SPRY2 Anticorps) coordination is required for normal development of the external genitalia in mice
conjunctival epithelial Spry1 and Spry2 (Montrer SPRY2 Anticorps) redundantly promote eyelid closure.
Findings demonstrate that Pokemon (Montrer ZBTB7A Anticorps) suppresses Sprouty1 expression through a miR (Montrer MLXIP Anticorps)-21-mediated mechanism, affecting the growth and proliferation of liver cancer cells.
May function as an antagonist of fibroblast growth factor (FGF) pathways and may negatively modulate respiratory organogenesis.
protein sprouty homolog 1
, sprouty, Drosophila, homolog of, 1 (antagonist of FGF signaling)
, sprouty 1 protein
, sprouty homolog 1, antagonist of FGF signaling (Drosophila)
, sprouty homolog 1, antagonist of FGF signaling
, sprouty 1
, sprouty homolog 1a, antagonist of FGF signaling
, sprouty homolog 1b, antagonist of FGF signaling
, inhibitor of receptor tyrosine kinases